Table 4.
MR estimates examining the association of genetically proxied perturbation of GLP1R with site-specific and overall cancer risk
| Outcome | N (cases; controls) | OR (95% CI) | p value |
|---|---|---|---|
| Breast cancer | 122,977; 105,974 | 0.72 (0.33, 1.58) | 0.42 |
| ER+ breast cancer | 69,501; 105,974 | 0.81 (0.33, 2.01) | 0.65 |
| ER− breast cancer | 21,468; 105,974 | 0.48 (0.13, 1.71) | 0.26 |
| Colorectal cancer | 58,221; 67,694 | 1.36 (0.50, 3.68) | 0.55 |
| Colon cancer | 32,002; 64,159 | 1.94 (0.59, 6.33) | 0.27 |
| Rectal cancer | 16,212; 64,159 | 1.13 (0.25, 5.23) | 0.87 |
| Prostate cancer | 79,148; 61,106 | 0.87 (0.35, 2.14) | 0.76 |
| Advanced prostate cancera | 15,167; 58,308 | 0.99 (0.10, 9.51) | 0.99 |
| Overall cancer risk | 27,483; 372,016 | 1.21 (0.45, 3.26) | 0.70 |
ORs (95% CIs) are scaled to represent the effect of genetically proxied perturbation of GLP1R equivalent to a 1 unit lowering of IRNT HbA1c (mmol/mol)
aAdvanced prostate cancer is defined as metastatic disease, Gleason score ≥8, prostate-specific antigen >100 or prostate cancer-related death